The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | Isavuconazole treatment for fungal disease in leukemia patients
At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses isavuconazole for fungal disease treatment in leukemia patients. Isavuconazole has less toxicity than voriconazole and shows significant activity over mucormycosis. It has an oral and intravenous (IV) formulation which essential in treatments of sick patients.
